Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
309.6 USD | -1.23% | -1.60% | -14.32% |
May. 30 | JPMorgan Adjusts Price Target on Molina Healthcare to $420 From $435 | MT |
May. 30 | Baird Initiates Molina Healthcare With Outperform Rating, $405 Price Target | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The stock, which is currently worth 2024 to 0.37 times its sales, is clearly overvalued in comparison with peers.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company sustains low margins.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.32% | 18.14B | B- | ||
-6.80% | 452B | B- | ||
+14.29% | 125B | A- | ||
+12.91% | 96.05B | B- | ||
-23.16% | 42.39B | A- | ||
-5.93% | 37.25B | B- | ||
-25.77% | 2.63B | C+ | ||
+15.53% | 546M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MOH Stock
- Ratings Molina Healthcare, Inc.